BioSpace News Archive

KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM-1 expression in all treated areas following initial and repeat administration. KB105-expressed TGM1 was correctly localized in the epidermis, co-localizing with loricrin, and was functionally active Phenotypic evaluation of KB105 treated areas showed reduced reversion to ichthyotic scaling phenotype Amy Paller, M.D., Professor and Chair of Dermatology at Northwestern University

Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeks SVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow fibrosis seen across treatment arms Additional data to be presented at EHA from ~50 1L and 70-80 2L patients CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three abstracts relating to the MANIFEST clinical tr

The maker of breakthrough augmented-extended reality (AR/XR) glasses that provide a radically new surgical viewing experience for retinal surgeons and patients alike, is launching new technology that provides the most modern options for surgery visualization and to remove “pain” for surgeons to improve surgeries, Ocutrx Vision Technologies, LLC announced today.

OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that its abstract on the use of advanced bioinformatic analysis and machine learning tools on plasma proteomics in order to predict outcomes of immunotherapy-treated melanoma patients was accepted for the American Society of Clinical Oncology (ASCO) 2020 Virtual Poster Discussion Session.

ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced a change in the location of its 2020 Annual Meeting of Stockholders. In light of the COVID-19 pandemic and in an effort to protect the health and safety of the Company’s stockhold

Optical filters designed for real-time qPCR applications / COVID-19 testing can be ordered online now.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology today reports its Q1 2020 financial results and provides a business update.

Menarini Ricerche announces the completion of the dose escalation part of the First in Human, phase I/II DIAMOND trial currently ongoing to evaluate SEL24/MEN1703, a first in class, oral dual PIM/FLT3 inhibitor in development for the treatment of acute myeloid leukemia.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including topline data from the Phase 1 clinical trial of KER-050, at

bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25 th European Hematology Association Annual Congress Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of healthy red blood cell production in patients with transfusion-dependent β-thalassemia